A review of 65 years of human adenovirus seroprevalence

• Egile Nagusiak: Franck J. D. Mennechet (Egilea), Océane Paris (Egilea), Aline Raissa Ouoba (Egilea), Sofia Salazar Arenas (Egilea), Sodiomon B. Sirima (Egilea), Guy R. Takoudjou Dzomo (Egilea), Amidou Diarra (Egilea), Isidore T Traore (Egilea), Dramane Kania (Egilea), Karsten Eichholz (Egilea), Eric A. Weaver (Egilea), Edouard Tuaillon (Egilea), Eric J. Kremer (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2019-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types corre...